{"id":"NCT02057406","sponsor":"Wei Jiang","briefTitle":"Omega 3 for Treatment of Depression in Patients With Heart Failure","officialTitle":"Omega 3 for Comorbid Depression and Heart Failure Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2016-05-19","completion":"2016-12-02","firstPosted":"2014-02-07","resultsPosted":"2017-06-12","lastUpdate":"2018-05-14"},"enrollment":108,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depression"],"interventions":[{"type":"DRUG","name":"2:1 EPA/DHA","otherNames":["400 EPA/200 DHA 2 grams"]},{"type":"DRUG","name":"High EPA","otherNames":["An almost pure Eicosapentaenoic acid 2 grams"]},{"type":"OTHER","name":"Placebo","otherNames":["Matched placebo corn oil capsules"]}],"arms":[{"label":"2:1 EPA/DHA","type":"ACTIVE_COMPARATOR"},{"label":"High EPA","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Omega 3 supplements will improve depressive symptoms to a greater extent than placebo in heart failure patients with moderate to severe major depressive disorder.","primaryOutcome":{"measure":"Endpoint Hamilton Depression Rating Scale (HAMD) Scores Adjusted for Age, Sex, Treatment Site, and Baseline HAMD Scores.","timeFrame":"Week 12","effectByArm":[{"arm":"2:1 EPA/DHA","deltaMin":15.1,"sd":0.9},{"arm":"High EPA","deltaMin":15.7,"sd":0.9},{"arm":"Placebo","deltaMin":14.9,"sd":0.9}],"pValues":[{"comp":"OG000 vs OG002","p":"0.74"},{"comp":"OG001 vs OG002","p":"0.45"}]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":13},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":["34817851","30098961"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":36},"commonTop":["Cellulitis","Cataract Removal","Arrhythmia","Dehydration","Heart failure exacerbation"]}}